clinical trial · NCT03567824
MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus
Pharmalyte Solutions LLC·phase2·not yet recruiting·n = 200
Hypomagnesemia in Type 2 Diabetic PatientsMagnesium L-lactate dihydratePlacebo Oral Tablet
brief summary
To determine the effect of MLD10 (magnesium L-lactate dihydrate extended-release caplets) 10 mEq BID on serum magnesium in Type 2 diabetic patients with hypomagnesemia.
started
Mar 1, 2026
primary completion
Apr 30, 2028
completion
Apr 30, 2028
last updated
Nov 27, 2023
official title
A Phase 2 Open Label Study of Magnesium L-Lactate Dihydrate (MLD10) 10 mEq Extended-Release Caplets Administered BID for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus Followed by a Blinded Random Off Phase
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol